Results 161 to 170 of about 11,904 (210)
Some of the next articles are maybe not open access.
CNS Drugs, 2006
Rivastigmine is a carbamate-type dual inhibitor of brain acetyl- and butyrylcholinesterases that has been evaluated in the symptomatic treatment of patients with mild to moderate dementia associated with idiopathic Parkinson's disease. Oral rivastigmine 3-12 mg/day for 24 weeks was significantly more effective than placebo in ameliorating cognitive and
M Asif A, Siddiqui, Antona J, Wagstaff
openaire +2 more sources
Rivastigmine is a carbamate-type dual inhibitor of brain acetyl- and butyrylcholinesterases that has been evaluated in the symptomatic treatment of patients with mild to moderate dementia associated with idiopathic Parkinson's disease. Oral rivastigmine 3-12 mg/day for 24 weeks was significantly more effective than placebo in ameliorating cognitive and
M Asif A, Siddiqui, Antona J, Wagstaff
openaire +2 more sources
Journal of Clinical Pharmacology, 2009 The pharmacokinetics and pharmacodynamics of rivastigmine were compared in Japanese and white healthy participants who were given ascending single doses of the novel rivastigmine transdermal patch.
Gilbert Lefèvre +2 more
exaly +2 more sources
Hospital Medicine, 1999
The acetylcholinesterase inhibitors are the first useful and useable drugs for palliative treatment of dementia of the Alzheimer type. This article reviews the second-generation carbamate cholinesterase inhibitor, rivastigmine (EXELON®, Novartis, Basel) whose distinctive pharmacology is not only of immediate clinical relevance but also the key to some ...
openaire +2 more sources
The acetylcholinesterase inhibitors are the first useful and useable drugs for palliative treatment of dementia of the Alzheimer type. This article reviews the second-generation carbamate cholinesterase inhibitor, rivastigmine (EXELON®, Novartis, Basel) whose distinctive pharmacology is not only of immediate clinical relevance but also the key to some ...
openaire +2 more sources
Movement Disorders, 2006 We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyryleholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's ...
David J Burn, Murat Emre, Ian G Mckeith
exaly +2 more sources
The Neurologist, 2003
Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes. Butyrylcholinesterase in-creases as Alzheimer disease progresses, so its inhibition may become more important as the disease worsens.
openaire +2 more sources
Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes. Butyrylcholinesterase in-creases as Alzheimer disease progresses, so its inhibition may become more important as the disease worsens.
openaire +2 more sources